The lesions of gastric antral vascular ectasia take two endoscopic forms, diffuse red spots and red stripes. In addition, they are often associated with cirrhosis. The main aim of the present retrospective study was to determine whether differences in endoscopic appearance and presence or absence of cirrhosis have relationships to clinical features and course. Methods: Gastric antral vascular ectasia in 30 patients was classified into 2 endoscopic subtypes, punctate type (21 patients) and striped type (8 patients); only 1 patient could not be categorized to either type. The 30 patients were divided into groups based on the presence (25) or absence (5) of cirrhosis. Results: All patients with punctate-type vascular ectasias had cirrhosis, whereas only 38% of patients with the striped type had cirrhosis. All patients without cirrhosis had the striped pattern. For patients with the 2 endoscopic types as well as those with and without cirrhosis, the outcomes of endoscopic treatment were similar. 
Gastric antral vascular ectasia (GAVE) was initially described by Jabarri et al. 1 in 1984 and named "watermelon stomach" because of its endoscopic appearance; prominent erythematous "stripes" arranged radially around the pylorus. However, in 1984 Lee et al. 2 described two patients whose endoscopic examinations revealed diffuse red spots representing dilated blood vessels in the antrum. Thus, endoscopically, the lesions take two forms, striped and diffuse. The two types of GAVE have been considered identical because both are located within the antrum and have identical and specific histologic findings including dilation of mucosal capillaries with fibrin thrombi, fibromuscular hyperplasia of the lamina propria, and fibrohyalinosis around the ectatic capillaries. 3 The pathogenesis of GAVE remains unknown, but GAVE has been associated with a variety of diseases, including cirrhosis, [1] [2] [3] [4] autoimmune and connective tissue disorders, 4 and chronic renal failure. 4 Cirrhosis is frequently present in patients with GAVE, 5 and a close relation to GAVE has been suggested.
In the present study the endoscopic findings obtained from two different perspectives were analyzed, endoscopic type and presence or absence of cirrhosis, to clarify differences in clinical features and clinical course.
PATIENTS AND METHODS

Patients
Thirty consecutive patients in whom a diagnosis of GAVE was made between April 1993 and March 2000 and who had complete medical records were included in this retrospective study. Mean age was 68.7 years (range 59-84); 16 were men and 14 were women. The indications for the initial endoscopy were investigation of iron deficiency anemia (19 patients), screening for varices (10) , melena (2) , hematemesis (1) , and screening for upper GI diseases (1) . Although no patient was being treated with acidsuppressing drugs or β-blockers at the time of diagnosis of GAVE, 1 patient with rheumatoid arthritis was taking nonsteroidal anti-inflammatory drugs (NSAIDs) and 1 with systemic sclerosis was taking corticosteroids. The diagnosis of GAVE was based on endoscopic appearance and characteristic histologic findings as described above. The specimens, taken from the vascular ectasia in the antrum of all patients, were reviewed by a pathologist blinded to the clinical status. All patients underwent upper GI series, barium enema, EGD, and colonoscopy. Except for the stomach, no additional bleeding points were observed. In addition to the endoscopic findings, the following information was collected from case records: associated diseases, medications, laboratory findings (hemoglobin level, platelet count, serum urea nitrogen, serum creatinine, prothrombin activity), the Child-Pugh classification (determined only in patients with cirrhosis), abdominal radiologic and US findings, red blood cell transfusion requirements, the total time of endoscopic treatment, outcome of the treatment, and length of followup. During the course of follow-up 9 patients died of diseases other than GAVE; hepatocellular carcinoma in 5, multiple organic failure in 2, hepatic failure in 1, and chronic renal failure in 1. Informed consent was obtained from all patients after explanation of the nature and purpose of the study. The study protocol was approved by our institutional review board.
Endoscopic classification
The endoscopic photographs from each patient were reviewed independently by 3 experienced senior investigators who were blinded to clinical status, and patients were classified into one of two groups as follows: (1) punctuate type (21 patients) consisting of sharply demarcated, punctate red spots diffusely scattered throughout the antrum (Fig. 1A) , which on close observation appeared to consist of tortuous ectatic blood vessels; (2) striped type (8 patients) consisting of raised or flat erythematous folds radiating longitudinally from the pylorus (Fig. 1B) , each containing a visible convoluted column of vessels similar to those of punctate type and consistent with the description of "watermelon stomach" by Jabbari et al. 1 For 1 patient there was disagreement on the endoscopic type, and the findings could not be categorized to either type. The patient was a 76-year-old woman with a diagnosis of cirrhosis caused by hepatitis C virus. She was referred for evaluation of iron deficiency anemia. Endoscopy revealed discrete red patchy and punctate lesions, situated both on the folds and between the folds in the antrum (Fig. 1C) . This patient was Figure 1 . A, Endoscopic view of punctate-type GAVE showing clearly demarcated, punctate red spots diffusely scattered in the antrum. B, Endoscopic view of striped-type GAVE showing bright red columns that radiate outward from the pylorus. C, Endoscopic view of unclassified GAVE showing discrete erythematous patchy and punctate lesions situated both on the longitudinal folds and between the folds in the antrum. 
Classification by presence or absence of cirrhosis
Patients were divided into two groups according to the presence (25) or absence (5) of cirrhosis. The diagnosis of cirrhosis was established on the basis of liver biopsy in 19 patients and in the rest by a combination of clinical findings, liver function tests, and the ultrasonographic appearance of liver and spleen. Cirrhosis was excluded in all patients without cirrhosis by the absence of causes of chronic liver disease such as positive serum markers for hepatitis C or B virus and excessive alcohol consumption, the absence of ascites and splenomegaly by physical and US examinations, and the absence of a decrease in platelet count and prothrombin activity. These patients did not undergo liver biopsy. The length of follow-up was 25.0 ± 18.3 months for patients with cirrhosis and 19.0 ± 15.4 months for patients without cirrhosis (p = 0.478).
Endoscopic treatment
Twelve of 30 patients, who have had severe anemia and associated symptoms such as shortness of breath, fatigue, and dizziness, underwent endoscopic electrocoagulation with a monopolar probe (PSD-10, -20, Olympus Optical Co., Ltd., Tokyo, Japan) every week or two. The techniques of treatment were similar for the two endoscopic types. The probe was applied by using a power setting of 20 W until the lesions became ulcerated or eroded. The treatment time for each session ranged from 10 to 15 minutes. All patients were treated with sucralfate (3 g/day) for 3 to 4 weeks after endoscopic therapy. Treatment with NSAIDs (loxoprofen sodium 180 mg/day) for one patient with rheumatoid arthritis, and corticosteroids (prednisolone 5 mg/day) for one patient with systemic sclerosis were continued before and after the treatment. The end point for treatment was defined as complete or almost complete disappearance of the vascular ectasia. Follow-up endoscopies were performed at intervals of 4 to 6 months for the first 2 years and then repeated at the discretion of observers and whenever there was any suspicion of GI bleeding. Recurrence was defined as the observation of new abnormal vascular lesions and the recurrence of anemia after eradication of GAVE had been achieved. If there was a recurrence, further treatment was performed. Paired analyses before and after endoscopic treatment were made for hemoglobin level, transfusion index (the number of units transfused divided by the months of follow-up), and the total procedure time for endoscopic coagulation as a method of assessing the outcomes of treatment.
Statistical analysis
Quantitative variables (expressed as mean ± SD) were tested by using the paired t test and the unpaired t test when distribution was normal, otherwise by the Wilcoxon signed rank test and the Mann-Whitney test. Proportions were compared by the Fisher exact test. Correlation between the Child-Pugh classification and hemoglobin level in patients with cirrhosis was analyzed by the Pearson product moment correlation coefficient. A probability value of less than 0.05 was considered significant.
RESULTS
Comparison between endoscopic types
The characteristics of the two patient groups according to endoscopic findings are summarized in Table 1 . All patients with punctate-type GAVE had concurrent cirrhosis, whereas only 3 patients with striped-type GAVE (38%) had cirrhosis (p < 0.001).
In the punctate-type group, the cause of cirrhosis was viral in 15 patients, alcohol in 2, primary biliary cirrhosis in 1, and unknown in 3. In the striped-type group, cirrhosis was related to viral infection in 2 patients and to autoimmune hepatitis in 1. The frequency of esophageal varices was significantly higher in the punctate-type group (76%) than in the striped-type group (13%, p = 0.003). The proportions of patients with other associated disorders such as hepatocellular carcinoma, chronic renal disease, diabetes mellitus, hypothyroidism, Sjögren's syndrome, rheumatoid arthritis, and systemic sclerosis were similar in the two groups. The clinical findings for the two groups are listed in Table 2 . The mean hemoglobin level at diagnosis was significantly lower in the striped-type group (7.9 ± 2.6 g/dL) than in the punctate-type group (10.4 ± 2.6 g/dL, p = 0.034). Patients with punctatetype GAVE had significantly lower platelet counts and prothrombin activity (7.4 ± 2.2 ×10 4 /mm 3 , 72.2% ± 12.2%) compared with patients with striped-type GAVE (14.6 ± 5.3 ×10 4 /mm 3 , 93.1% ± 13.9%, p = 0.002, p < 0.001). There was no significant difference in Child-Pugh classification between the two groups. Three patients with punctate-type (14%) and 3 with striped-type GAVE (38%) were transfusiondependent.
Comparison between patients with and without cirrhosis
The background characteristics and endoscopic findings of the patient groups with and without cirrhosis are shown in Table 3 . The proportion of patients with cirrhosis who had esophageal varices was 72%. The frequencies of other associated disorders were similar in the two groups. Twenty-one patients with cirrhosis (84%) had punctate-type GAVE, 3 (12%) had striped-type GAVE (p <0.001), and 1 (4%) could not be categorized into either type. All patients without cirrhosis had striped-type GAVE (p <0.001).
The clinical findings for the two groups are listed in Table 4 . The mean hemoglobin level at diagnosis was significantly lower in patients without cirrhosis (7.2 ± 2.9 g/dL) compared with patients with cirrhosis (10.2 ± 2.5 g/dL, p = 0.022). In the group with cirrhosis, there was no significant correlation between the Child-Pugh classification and hemoglobin level (r = 0.0437, p > 0.05). Patients with cirrhosis had significantly lower platelet count and prothrombin activity (7.7 ± 2.3 ×10 4 /mm 3 , 73.8% ± 12.9%) compared with patients without cirrhosis (17.6 ± 3.7 ×10 4 /mm 3 , 95.4% ± 17.1%, p < 0.001, p = 0.003).
Three patients with cirrhosis (12%) and 3 without cirrhosis (60%) were blood-transfusion-dependent.
Outcome of treatment
The results of endoscopic therapy in the group with punctate-type GAVE and those with the striped type are shown in Table 2 . Five patients with punctate-type GAVE (24%) and 6 with striped-type GAVE (75%) were treated by endoscopic electrocoagulation. One patient with striped-type GAVE in the antrum had vascular ectasias in the cardia and underwent electrocoagulation therapy for both the antrum and cardia. The mean pretreatment hemoglobin level for 11 patients who underwent therapy was 7.2 g/dL (range 4.6-10.2). The total time of electrocoagulation was longer in patients with striped-type GAVE (55.3 ± 33.4 minutes) than in patients with punctate-type GAVE (37.4 ± 22.5 minutes), but the differences did not reach statistical significance (p = 0.126). The mean hemoglobin level improved significantly from 7.6 ± 2.1 to 11.6 ± 1.1 g/dL in patients with punctate type in response to treatment (p = 0.003), and significantly from 6.8 ± 1.7 to 10.8 ± 2.1 g/dL in patients with striped type (p = 0.008). In all patients who underwent therapy, the mean follow-up period was 28.0 months (range 1-67). One patient with punctatetype GAVE and 2 with striped-type GAVE died of associated disorders without signs of recurrent GI bleeding within 1 year. In 3 of the remaining 8 patients, 1 with punctate-type and 2 with striped-type GAVE, follow-up endoscopies revealed recurrence of vascular ectasia within 5 to 10 months of the previous treatment, and additional blood transfusions and electrocoagulation treatment were given. However, a significant decrease in transfusion requirement was found in both as determined by the transfusion index (from 3.4 ± 0.7 to 0.1 ± 0.2, p = 0.024, from 3.4 ± 0.6 to 0.2 ± 0.3, p = 0.016). The total time required for further electrocoagulation therapy was 3.0 ± 6.7 minutes in the punctate-type group and 11.7 ± 19.2 minutes in the striped-type group (p = 0.662), and these were significantly shorter than the total time of initial electrocoagulation therapy in both groups (p = 0.024, p = 0.003, respectively). The 8 survivors were no longer transfusion-dependent and had stable hemoglobin levels during a mean follow-up of 25.6 months (range 1-49). Between the punctate-type and striped-type groups, the recurrence rates after endoscopic treatment were similar (20% vs. 33%, p = 1.000).
No patients died of bleeding from GAVE; the mortality rate was 33% for the 21 patients with punctate-type and 25% for 8 patients with striped-type GAVE; this difference was not significant (p = 1.000). In patients who underwent endoscopic treatment, the mortality was also similar between the two groups (20% vs. 33%, p = 1.000).
The results of endoscopic therapy in patients with and without cirrhosis are shown in Table 4 . Eight patients with cirrhosis (32%) and 4 without cirrhosis (80%) were treated by endoscopic electrocoagulation. One patient without cirrhosis with striped-type GAVE had vascular ectasia in the cardia and underwent electrocoagulation of both areas. The mean pretreatment hemoglobin level for 12 patients who underwent coagulation therapy was 7.3 g/dL (range 4.6-10.2). The total time required for electrocoagulation was longer in patients without cirrhosis (56.3 ± 42.5 minutes) compared with patients with cirrhosis (41.0 ± 19.3 minutes), but the difference was not significant (p = 0.464). The mean hemoglobin level improved significantly from 7.9 ± 1.7 to 11.5 ± 1.0 g/dL in patients with cirrhosis in response to treatment (p < 0.001) and significantly from 6.1 ± 1.5 to 10.4 ± 2.0 g/dL in patients without cirrhosis (p = 0.049). In all patients who underwent therapy, the mean follow-up period was 25.6 months (range 1-67). One patient with cirrhosis and 2 without cirrhosis died of associated diseases without signs of recurrent GI bleeding within 1 year. Three of the remaining 9 patients, 2 with and 1 without cirrhosis, received additional blood transfusions and electrocoagulation for recurrent bleeding. However, a significant decrease in the transfusion index was found in both groups with and without cirrhosis after the initial treatment (from 3.4 ± 0.7 to 0.1 ± 0.2, p = 0.024, from 3.4 ± 0.6 to 0.2 ± 0.3, p = 0.016). The total time required for further electrocoagulation therapy was 5.0 ± 9.7 minutes in the punctate-type group and 11.3 ± 22.5 minutes in the striped-type group (p = 0.933), both of which were shorter than the total time for initial electrocoagulation (p = 0.002, p = 0.125, respectively). In 8 patients with cirrhosis who underwent therapy, there was no significant difference in the Child-Pugh classification between 2 patients who had additional therapy and 6 without (6.0 ± 0.0 vs. 6.8 ± 1.0, p = 0.299). The 9 survivors 7.9 ± 1.7 6.1 ± 1. without recurrence of bleeding were no longer transfusion-dependent and had stable hemoglobin levels during a mean follow-up of 20.2 months (range 1-49).
Between the group with and the group without cirrhosis, the recurrence rates after treatment in the patients who underwent endoscopic therapy were similar (25% vs. 25%, p = 1.000).
The mortality was 28% for all 25 patients with cirrhosis and 40% for the 5 patients without cirrhosis; the difference was not significant (p = 0.622). In patients who underwent endoscopic treatment, the mortality rate was similar between the groups with and without cirrhosis (12.5% vs. 50%, p = 0.236).
DISCUSSION
In the present study, all patients with punctatetype GAVE had concurrent cirrhosis. The majority of patients with cirrhosis had punctate-type GAVE. In contrast, all patients without cirrhosis had stripedtype GAVE. The endoscopic appearance of the punctate type was highly specific. Lee et al. 2 described 2 patients in whom endoscopy revealed diffuse red antral speckling due to dilated blood vessels. One had cirrhosis but the other did not. Red lesions in the patient without cirrhosis were described as "multiple small red areas of varying size." This description appears to be identical to that for the patient who could not be classified. Some patients reported to have a diffuse type of GAVE may be divided into at least 3 types: (1) punctate, (2) speckled (varying sizes), and (3) striped ("watermelon stomach"). The speckled type may be a mixture of punctate and striped types, or the early stage of the striped type, because the erythematous lesions are arrayed longitudinally on the folds with satellites of red spots interspersed among the folds. There are endoscopic differences between the classic diffuse type described previously and the diffuse type defined in the present study, that is, the punctate type in which there are sharply demarcated red "punctate" lesions of nearly even size that are diffusely scattered in the antrum. This type can be referred to as the "punctate type of gastric antral vascular ectasia (P-GAVE)." The present findings suggest that P-GAVE is associated with cirrhosis without exception, whereas the simultaneous occurrence of striped-type GAVE and cirrhosis is less frequent.
More severe anemia was observed in the patient group with striped-type GAVE and the patient group without cirrhosis compared with the other groups at the time of diagnosis, and, consequently, a longer time was probably required to control bleeding due to GAVE by electrocoagulation. The present findings do not necessarily suggest that striped type and non-cirrhotic status represent a more advanced stage of the disease. They may be caused by differences in the indications for initial endoscopic examination between the two groups. Ten of 25 cirrhotic patients underwent initial endoscopy for screening for varices and the rest for anemia. GAVE is occasionally diagnosed at an early stage of the disease in patients with cirrhosis because endoscopies are routinely performed to screen for evidence of portal hypertension, whereas anemia is often severe in patients with GAVE without cirrhosis because they undergo endoscopy in response to anemia. Therefore, it remains unclear whether striped-type GAVE and noncirrhotic status represent a more serious type of the disorder.
Platelet count and prothrombin activity were lower in the punctate-type group than the stripedtype group. These findings appear to be due to the fact that all patients with punctate-type GAVE had associated cirrhosis. In contrast, patients with striped-type GAVE and patients without cirrhosis had normal platelet counts and prothrombin activity. These findings suggest that neither platelet count nor prothrombin activity influence bleeding due to GAVE. The severity of liver dysfunction was not related to the degree of bleeding in the present study because for patients with cirrhosis there was no significant correlation between the Child-Pugh classification and hemoglobin level, and there was no significant difference in the Child-Pugh classification between patients with and without further electrocoagulation therapy.
Electrocoagulation was performed in 12 patients. The improvement in hemoglobin level, the reduction in the transfusion index, and the shortening of total electrocoagulation time were observed after therapy without complications. These findings suggested that electrocoagulation is effective and safe for bleeding from GAVE. Moreover, the outcome of the therapy was similar irrespective of endoscopic appearance and the presence of cirrhosis. No patient died of blood loss from GAVE, and the mortality during the follow-up period was similar between the two groups. Considering the above findings, it was concluded that endoscopic type and presence or absence of cirrhosis had no influence on the response to endoscopic treatment.
In 3 patients in the present study vascular ectasias were also observed in the cardia. One patient without cirrhosis, with a hiatal hernia, had the striped-type vascular ectasias in the antrum and underwent electrocoagulation of both the antrum and cardia. Two patients with cirrhosis without a hiatal hernia had punctate-type GAVE but did not undergo endoscopic treatment because they did not have either severe anemia or symptoms of anemia. Vascular ectasias in had no influence on the response to endoscopic treatment and mortality. These findings do not suggest that punctate-type and striped-type GAVE may be distinctive entities or that the conditions with and without cirrhosis may be different. Further studies are needed to clarify the pathogenesis of GAVE and the relationship between GAVE and cirrhosis and to determine the factors leading to differences between the two endoscopic types. Even if these issues remain unclear, whenever P-GAVE is observed in the stomach of a patient, regardless of the presence or absence of anemia, a careful investigation for the presence of cirrhosis should be undertaken.
